Market Overview - The precision medicine sector experienced a slight decline of 0.01% on November 12, with Guomai Technology leading the drop [1] - The Shanghai Composite Index closed at 4000.14, down 0.07%, while the Shenzhen Component Index closed at 13240.62, down 0.36% [1] Stock Performance - Zhongyuan Xiehe saw a significant increase of 10.00%, closing at 28.61 with a trading volume of 311,400 shares and a transaction value of 857 million [1] - Yangpu Medical and Beilu Pharmaceutical also reported gains of 4.13% and 2.96%, respectively [1] - Guomai Technology, on the other hand, declined by 3.17%, closing at 11.62 [2] Capital Flow - The precision medicine sector saw a net inflow of 311 million from institutional investors, while retail investors experienced a net outflow of 318 million [2] - Major stocks like Zhongyuan Xiehe and Yaoming Kangde attracted significant institutional investment, with net inflows of 1.941 billion and 76.27 million, respectively [3] Individual Stock Highlights - Zhongyuan Xiehe had a net institutional inflow of 1.941 billion, accounting for 22.65% of its trading volume, while retail investors withdrew 932 million [3] - Yaoming Kangde also saw a net institutional inflow of 76.27 million, with retail investors withdrawing 430 million [3] - Other notable stocks with positive institutional inflows include Beilu Pharmaceutical and Yangpu Medical, with net inflows of 33.03 million and 26.56 million, respectively [3]

Market Overview - The precision medicine sector experienced a decline of 1.77% on November 4, with TuoJing Life leading the drop [1][2] - The Shanghai Composite Index closed at 3960.19, down 0.41%, while the Shenzhen Component Index closed at 13175.22, down 1.71% [1] Stock Performance - Notable stock performances in the precision medicine sector included: - RenDu Bio (688193) closed at 52.90, up 1.05% with a trading volume of 7076.23 hands and a transaction value exceeding 36.99 million yuan [1] - TuoJing Life (300642) closed at 22.73, down 2.86% with a trading volume of 78,200 hands and a transaction value of 178 million yuan [2] - Other companies like DaAn Gene (002030) and Anke Bio (300009) showed minimal changes, with DaAn Gene remaining flat at 6.57 and Anke Bio down 0.55% to 10.84 [1][2] Capital Flow - The precision medicine sector saw a net outflow of 979 million yuan from institutional investors, while retail investors contributed a net inflow of 642 million yuan [2][3] - Specific stock capital flows indicated: - GuoMai Technology (002093) had a net inflow of 8.61 million yuan from institutional investors, while retail investors saw a net outflow of 15.98 million yuan [3] - TuoJing Life experienced minimal net inflow from institutional investors at 25,000 yuan, with retail investors also showing a slight outflow [3]

上海仁度生物科技股份有限公司 2025 年第一次临时股东大会会议资料 证券代码：688193 证券简称：仁度生物 上海仁度生物科技股份有限公司 2025 年第一次临时股东大会会议资料 2025 年 11 月 上海仁度生物科技股份有限公司 2025 年第一次临时股东大会会议资料 目 录 | 议案一 | 关于公司变更注册资本、取消监事会并修订《公司章程》的议案 | 6 | | --- | --- | --- | | 议案二 | 关于公司修订部分内部管理制度的议案 | 8 | | 议案三 | 关于公司为董事、高级管理人员购买责任保险的议案 | 9 | 上海仁度生物科技股份有限公司 2025 年第一次临时股东大会会议资料 2025 年第一次临时股东大会会议须知 为了维护全体股东的合法权益，确保股东大会的正常秩序和议事效率，保证 大会的顺利进行，根据《中华人民共和国公司法》（以下简称"《公司法》"）《中 华人民共和国证券法》（以下简称"证券法"）《上市公司股东大会规则》以及《上 海仁度生物科技股份有限公司章程》（以下简称"《公司章程》"）《上海仁度生 物科技股份有限公司股东大会议事规则》等相关规定，上海仁度生物科技股份 ...

Core Insights - The medical device sector experienced a rise of 1.13% on October 31, with Caina Co., Ltd. leading the gains [1] - The Shanghai Composite Index closed at 3954.79, down 0.81%, while the Shenzhen Component Index closed at 13378.21, down 1.14% [1] Medical Device Sector Performance - Caina Co., Ltd. (301122) saw a closing price of 30.38, with a significant increase of 19.98% and a trading volume of 91,000 shares, amounting to a transaction value of 259 million [1] - Spring Medical (688236) closed at 28.88, up 14.47%, with a trading volume of 84,200 shares and a transaction value of 235 million [1] - ZhenDe Medical (603301) closed at 95.00, increasing by 9.07% with a trading volume of 211,900 shares, resulting in a transaction value of 1.951 billion [1] - Other notable performers included TuoJing Life (300642) with an 8.81% increase, and Rejing Bio (688068) with an 8.70% increase [1] Capital Flow Analysis - The medical device sector saw a net inflow of 475 million from institutional investors, while retail investors experienced a net outflow of 108 million [2][3] - Major stocks like Mindray Medical (300760) had a net inflow of 262 million from institutional investors, but a net outflow of 1.27 billion from retail investors [3] - Other stocks such as Furuishi (300049) and Lepu Medical (300003) also showed significant net inflows from institutional investors, indicating strong institutional interest [3]

Core Insights - RenDu Bio (688193.SH) reported its Q3 2025 results on October 31, 2025, highlighting a total of 6 institutional investors holding shares, amounting to 13.6487 million shares, which represents 34.06% of the total share capital [1] Institutional Holdings - The total institutional holding percentage decreased by 3.26 percentage points compared to the previous quarter [1] - The institutional investors include MING LI INVESTMENTS LIMITED, Changzhou Jin Xin Venture Capital Co., Ltd., CENTRAL CHIEF LIMITED, Runcong (Shanghai) Enterprise Management Center (Limited Partnership), Nanjing Gaoke Xinjun Growth Phase I Equity Investment Partnership (Limited Partnership), and CICC-Pudong Development Bank-CICC Fengzhong No. 41 Employee Participation in Sci-Tech Innovation Board Strategic Allocation Collective Asset Management Plan [1] Public Fund Activity - A total of 31 public funds were disclosed this period, including Huaxia Pantai Mixed (LOF) A, Huaxia New Jinxiu Mixed A, GF Multi-Factor Mixed, Huashang Quantitative Quality Selected Mixed, and E Fund Shanghai Stock Exchange Sci-Tech Innovation Board Comprehensive ETF [1] Foreign Investment Trends - One foreign fund, CENTRAL CHIEF LIMITED, reduced its holdings by 1.00% compared to the previous quarter [1]

Core Insights - The company reported a revenue of 37,912,427.65 yuan for the third quarter of 2025, representing a year-on-year decline of 13.76% [2] - The net profit attributable to shareholders of the listed company was 4,975,755.59 yuan, showing a significant year-on-year increase of 1361.80% [2] Financial Performance - Revenue for Q3 2025: 37.91 million yuan, down 13.76% year-on-year [2] - Net profit for Q3 2025: 4.98 million yuan, up 1361.80% year-on-year [2]

Core Insights - The company, established in June 2007 and listed on the Shanghai Stock Exchange in March 2022, is a leading domestic RNA precision diagnostics enterprise with a focus on molecular diagnostic reagents and instruments, leveraging SDA technology for competitive advantage [1] Financial Performance - For Q3 2025, the company reported revenue of 119 million yuan, ranking 38th in the industry, significantly lower than the top competitor's revenue of 3.428 billion yuan and the second competitor's 3.127 billion yuan, as well as below the industry average of 708 million yuan and median of 330 million yuan [2] - The main business composition includes reagent sales at 73.15 million yuan (90.04%), instrument sales at 6.89 million yuan (8.49%), and testing services at 1.19 million yuan (1.47%) [2] - The net profit for the same period was 7.01 million yuan, ranking 23rd in the industry, again trailing behind the leading competitor's net profit of 1.588 billion yuan and the second competitor's 1.205 billion yuan, as well as below the industry average of 110 million yuan and median of 26.19 million yuan [2] Financial Ratios - The company's debt-to-asset ratio for Q3 2025 was 7.25%, a decrease from 7.76% in the previous year, and significantly lower than the industry average of 18.29%, indicating lower debt pressure [3] - The gross profit margin for Q3 2025 was 77.75%, down from 80.39% year-on-year, but still well above the industry average of 56.20%, reflecting strong profitability [3] Executive Compensation - The chairman, Ju Jinliang, received a salary of 2.0472 million yuan in 2024, an increase of 54,000 yuan from 2023 [4] - The general manager, Yu Minghui, earned 1.0415 million yuan in 2024, a decrease of 684,000 yuan from the previous year [4] Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 7.73% to 3,765, with an average holding of 10,600 circulating A-shares, up 17.83% from the previous period [5]

Core Insights - The 24th National Andrology Academic Conference was successfully held, gathering numerous experts to discuss the latest research and clinical advancements in male health [1] - Rendu Biotech, a leader in RNA molecular diagnostic technology, showcased its advanced products for diagnosing reproductive tract infections and announced a strategic partnership with Xiamen Baiouxin Biotechnology Co., Ltd. to explore new areas in genetic infertility diagnosis [1][2] Group 1 - Rendu Biotech presented its nucleic acid detection series for reproductive tract pathogens, covering common pathogens such as Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), Mycoplasma genitalium (MG), and Ureaplasma urealyticum (UU) [1] - The RNA-SAT technology used in these products offers significant advantages over traditional DNA detection methods, allowing for the detection of pathogen RNA, which only exists in living pathogens, thus effectively distinguishing between current and past infections [1][2] - The product supports various sample types, including urine and swabs, enabling non-invasive sampling, which significantly enhances patient compliance and testing convenience [1] Group 2 - During the conference, Rendu Biotech and Baiouxin signed a strategic cooperation agreement to market the "Y Chromosome Microdeletion and Klinefelter Syndrome (XXY) Gene Testing Kit" [2] - This kit has recently been approved by the National Medical Products Administration for genetic cause screening in male infertility patients, targeting the primary genetic pathogenic factors in this patient group [2] - The combination of Rendu Biotech's pathogen detection series and the new genetic testing solution provides a comprehensive "infection + genetics" integrated solution for clinical needs in male infertility diagnosis [2][3] Group 3 - The industry views Rendu Biotech's focus on RNA molecular diagnostics as a commitment to meet unmet clinical needs through technological innovation [3] - The conference not only highlighted Rendu Biotech's technological leadership in reproductive tract infection diagnostics but also its collaborative efforts with Baiouxin to expand its overall presence in male health testing [3]

证券代码：688193 证券简称：仁度生物 公告编号：2025-046 关于公司召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 11 月 18 日（星期二）16:00-17:00 会议召开地点：上海证券交易所上证路演中心（网址： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 11 月 11 日（星期二）至 11 月 17 日（星期一）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@rdbio.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 上海仁度生物科技股份有限公司（以下简称"公司"）已于 2025 年 10 月 31 日发布公司 2025 年第三季度报告，为便于广大投资者更全面深入地了解公司 2025 年第三季度经营成果、财务状况，公司计划于 2025 年 11 月 18 日（星期二） 16:00-17:0 ...

证券代码：688193 证券简称：仁度生物 公告编号：2025-045 上海仁度生物科技股份有限公司 关于公司为董事、高级管理人员购买责任保险的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 为进一步完善公司风险管理体系，防范运营风险，促进公司董事、高级管理 人员充分履职，保障广大投资者的利益，根据《上市公司治理准则》等相关规定， 上海仁度生物科技股份有限公司（以下简称"公司"）拟为公司及公司全体董事、 高级管理人员等购买责任保险（以下简称"责任保险"）。 现将有关事项公告如下： 2、被保险人：公司及公司全体董事、高级管理人员及其他相关主体（具 体以保险合同为准） 3、赔偿限额：不超过人民币20,000,000元（具体以保险合同为准） 4、保费支出：不超过人民币10万元/年（具体以保险合同为准） 5、保险期限：12个月（后续每年可续保或重新投保） 一、具体方案 1、投保人：上海仁度生物科技股份有限公司 准则》等相关规定及列明的责任保险方案，为公司全体董事、高级管理人员购 买责任保险。 二、审议程序 （一）董事会会议的 ...